Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth K Lee

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
JCO Precision Oncology|April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker AnalysesPanagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Nature Medicine|June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsTimothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b ResultsEzra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
Gynecologic Oncology|May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancerElizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
The Lancet. Oncology|June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trialPanagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
JCO Precision Oncology|April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker AnalysesPanagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Nature Medicine|June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsTimothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b ResultsEzra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
Gynecologic Oncology|May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancerElizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
The Lancet. Oncology|June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trialPanagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
Pageof 4